Vaccine Coverage Associated With Ending a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Wave: A Retrospective Longitudinal Analysis
Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e207-e215
DOI: 10.1093/cid/ciac524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 10.08.2022. Verfasst von Aharona Glatman-Freedman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Two SARS-CoV-2 waves in Israel ended while a substantial number of individuals remained unvaccinated or partially vaccinated. The indirect protective effect of the first BNT162b2 vaccination campaign in Israel was evaluated between 22 December 2020 and 18 May 2021.
Methods
The daily percentage of new polymerase chain reaction (PCR)–confirmed SARS-CoV-2 cases among unvaccinated individuals was analyzed for trends. Major shifts were identified using piecewise linear regression analysis. At these shifts, the percentage of naturally vaccinated (past SARS-CoV-2 cases) and the percentage of actively vaccinated (by inoculation) individuals were weighted and summed to determine the percentage of natural and active vaccination (NAV).
Results
A first decline among unvaccinated individuals occurred during a lockdown period, when the percentage of NAV was 8.16%. The major decline occurred after the end of the lockdown when the percentage of NAV reached 52.05%. SARS-CoV-2 cases ultimately declined among unvaccinated individuals when the percentage of NAV reached 63.55%. During the study period, the Alpha variant was prevalent and the use of nonpharmaceutical interventions, including social distancing, existed to varying degrees.
Conclusions
The vaccination campaign played a major role in the decline of SARS-CoV-2 infection among unvaccinated individuals, leading to the end of the first 2021 SARS-CoV-2 wave (Alpha variant) in Israel. Infection in unvaccinated individuals stopped when two-thirds of the population were naturally or actively vaccinated. Any change in characteristics of the virus or the population can lead to a new outbreak.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel.
- Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- National Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
- School of Public Health, Haifa University, Haifa, Israel.
ORCID-Profile: Aharona Glatman-Freedman
Zitieren
APA
Glatman-Freedman, A., Feldman, S. F., Hershkovitz, Y., Kaufman, Z., Dichtiar, R., Keinan-Boker, L., & Bromberg, M. (2023). Vaccine Coverage Associated With Ending a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Wave: A Retrospective Longitudinal Analysis. Clinical Infectious Diseases, 76(3), e207-e215. https://doi.org/10.1093/cid/ciac524
Vancouver
Glatman-Freedman A, Feldman SF, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, et al. Vaccine Coverage Associated With Ending a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Wave: A Retrospective Longitudinal Analysis. Clinical Infectious Diseases. 2023;76(3):e207-e215. doi:10.1093/cid/ciac524
BibTeX
@article{GlatmanFreedman2023,
author = {Glatman-Freedman, Aharona and Feldman, Sarah F and Hershkovitz, Yael and Kaufman, Zalman and Dichtiar, Rita and Keinan-Boker, Lital and Bromberg, Michal},
title = {Vaccine Coverage Associated With Ending a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Wave: A Retrospective Longitudinal Analysis},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {3},
pages = {e207--e215},
doi = {10.1093/cid/ciac524}
}
EUVIMED